Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Portfolio Pulse from
Northwell Health Cancer Institute has joined RenovoRx's Phase III TIGeR-PaC clinical trial, aiming for full patient enrollment by mid-2025.
November 20, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RenovoRx's ongoing Phase III TIGeR-PaC clinical trial has gained a new clinical site with Northwell Health Cancer Institute joining. The company aims to complete patient enrollment by the first half of 2025.
The addition of Northwell Health Cancer Institute as a clinical site for RenovoRx's Phase III trial is a positive development, potentially accelerating the trial's progress and increasing the likelihood of reaching full enrollment by 2025. This could enhance investor confidence in RenovoRx's pipeline and future prospects.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90